Journal Club - March 10, 2022
Andrew Kochan presented the PARADISE-MI Trial. The trial’s goal was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in the acute myocardial infarction (AMI) population. This trial enrolled 5661 patients with a duration of follow-up of 23 months. It was published in the NEJM in May last year.